Piroxicam Delays Tumor Growth and Metastasis in Mice
Author Information
Author(s): P.A. Fontan, C.R. Amura, D.O. Sordelli
Primary Institution: Departamento de Microbiologia, Parasitologia e Inmunologia, Facultad de Medicina, Universidad de Buenos Aires, Argentina
Hypothesis
Does treatment with piroxicam delay the growth of a mammary adenocarcinoma and its metastases?
Conclusion
Piroxicam treatment significantly delays the growth of pulmonary metastases and increases survival in mice with a mammary adenocarcinoma.
Supporting Evidence
- Piroxicam treatment significantly decreased the size of the primary tumor.
- Survival of mice bearing the primary tumor was significantly lengthened by anti-inflammatory treatment.
- Piroxicam treatment inhibited the growth of pulmonary metastases in a dose-related fashion.
Takeaway
Giving mice a medicine called piroxicam helps them live longer and stops their tumors from growing as fast.
Methodology
Mice were treated with piroxicam and their tumor growth and survival rates were measured after surgical removal of the primary tumor.
Potential Biases
Potential bias in treatment effects due to the non-blinded nature of some assessments.
Limitations
Only piroxicam was tested, and the study was conducted in a murine model, which may not fully represent human responses.
Participant Demographics
Male and female Balb/c mice, aged 8-12 weeks.
Statistical Information
P-Value
0.029
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website